{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T16:02:52Z","timestamp":1784563372643,"version":"3.55.0"},"reference-count":43,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,10,4]],"date-time":"2023-10-04T00:00:00Z","timestamp":1696377600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100014180","name":"Junta de Castilla y Le\u00f3n","doi-asserted-by":"publisher","award":["GRS 2322\/A\/21"],"award-info":[{"award-number":["GRS 2322\/A\/21"]}],"id":[{"id":"10.13039\/501100014180","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100014180","name":"Junta de Castilla y Le\u00f3n","doi-asserted-by":"publisher","award":["SA074P20"],"award-info":[{"award-number":["SA074P20"]}],"id":[{"id":"10.13039\/501100014180","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008666","name":"Fundaci\u00f3 la Marat\u00f3 de TV3","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008666","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014440","name":"Ministerio de Ciencia, Innovaci\u00f3n y Universidades","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014440","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100015755","name":"Centro de Investigaci\u00f3n Biom\u00e9dica en Red de Enfermedades Hep\u00e1ticas y Digestivas","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100015755","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002704","name":"Fundaci\u00f3n Cient\u00edfica Asociaci\u00f3n Espa\u00f1ola Contra el C\u00e1ncer","doi-asserted-by":"publisher","award":["AECC2023\/2027"],"award-info":[{"award-number":["AECC2023\/2027"]}],"id":[{"id":"10.13039\/501100002704","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["PI19\/00819"],"award-info":[{"award-number":["PI19\/00819"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["PI20\/00189"],"award-info":[{"award-number":["PI20\/00189"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["PI22\/00526"],"award-info":[{"award-number":["PI22\/00526"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008530","name":"European Regional Development Fund","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008530","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100014064","name":"University of Salamanca","doi-asserted-by":"publisher","award":["PC_TCUE21\u201323_011"],"award-info":[{"award-number":["PC_TCUE21\u201323_011"]}],"id":[{"id":"10.13039\/501100014064","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine & Pharmacotherapy"],"published-print":{"date-parts":[[2023,12]]},"DOI":"10.1016\/j.biopha.2023.115658","type":"journal-article","created":{"date-parts":[[2023,10,11]],"date-time":"2023-10-11T11:34:32Z","timestamp":1697024072000},"page":"115658","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"special_numbering":"C","title":["Evaluation of potential targets to enhance the sensitivity of cholangiocarcinoma cells to anticancer drugs"],"prefix":"10.1016","volume":"168","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2649-8778","authenticated-orcid":false,"given":"Paula","family":"Sanchon-Sanchez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oscar","family":"Briz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rocio I.R.","family":"Macias","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar","family":"Abad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anabel","family":"Sanchez-Martin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose J.G.","family":"Marin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7714-1691","authenticated-orcid":false,"given":"Elisa","family":"Lozano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.biopha.2023.115658_bib1","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1038\/s41572-021-00300-2","article-title":"Cholangiocarcinoma","volume":"7","author":"Brindley","year":"2021","journal-title":"Nat. Rev. Dis. Prim."},{"issue":"2","key":"10.1016\/j.biopha.2023.115658_bib2","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1038\/nrclinonc.2017.157","article-title":"Cholangiocarcinoma - evolving concepts and therapeutic strategies","volume":"15","author":"Rizvi","year":"2018","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"9","key":"10.1016\/j.biopha.2023.115658_bib3","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1038\/s41575-020-0310-z","article-title":"Cholangiocarcinoma 2020: the next horizon in mechanisms and management","volume":"17","author":"Banales","year":"2020","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"issue":"2","key":"10.1016\/j.biopha.2023.115658_bib4","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/j.jhep.2019.11.020","article-title":"Liver resection and transplantation for intrahepatic cholangiocarcinoma","volume":"72","author":"Mazzaferro","year":"2020","journal-title":"J. Hepatol."},{"issue":"1","key":"10.1016\/j.biopha.2023.115658_bib5","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.jhep.2023.03.010","article-title":"European association for the study of the, EASL-ILCA clinical practice guidelines on the management of intrahepatic cholangiocarcinoma","volume":"79","year":"2023","journal-title":"J. Hepatol."},{"issue":"6","key":"10.1016\/j.biopha.2023.115658_bib6","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1016\/S2468-1253(22)00043-7","article-title":"Gemcitabine and cisplatin plus durvalumab with or without tremelimumab in chemotherapy-naive patients with advanced biliary tract cancer: an open-label, single-centre, phase 2 study","volume":"7","author":"Oh","year":"2022","journal-title":"Lancet Gastroenterol. Hepatol."},{"issue":"2","key":"10.1016\/j.biopha.2023.115658_bib7","first-page":"198","article-title":"Advances in the treatment of intrahepatic cholangiocarcinoma: an overview of the current and future therapeutic landscape for clinicians","volume":"73","author":"Moris","year":"2023","journal-title":"CA Cancer J. Clin."},{"issue":"5","key":"10.1016\/j.biopha.2023.115658_bib8","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1016\/S1470-2045(21)00027-9","article-title":"Second-line FOLFOX chemotherapy versus active symptom control for advanced biliary tract cancer (ABC-06): a phase 3, open-label, randomised, controlled trial","volume":"22","author":"Lamarca","year":"2021","journal-title":"Lancet Oncol."},{"issue":"8","key":"10.1016\/j.biopha.2023.115658_bib9","doi-asserted-by":"crossref","first-page":"889","DOI":"10.2174\/1389450116666150223121508","article-title":"Molecular bases of chemoresistance in cholangiocarcinoma","volume":"18","author":"Marin","year":"2017","journal-title":"Curr. Drug Targets"},{"issue":"7","key":"10.1016\/j.biopha.2023.115658_bib10","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1038\/s41416-020-0987-3","article-title":"Current and novel therapeutic opportunities for systemic therapy in biliary cancer","volume":"123","author":"Marin","year":"2020","journal-title":"Br. J. Cancer"},{"issue":"4 Pt B","key":"10.1016\/j.biopha.2023.115658_bib11","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1016\/j.bbadis.2017.06.005","article-title":"Chemoresistance and chemosensitization in cholangiocarcinoma","volume":"1864","author":"Marin","year":"2018","journal-title":"Biochim Biophys. Acta Mol. Basis Dis."},{"issue":"4","key":"10.1016\/j.biopha.2023.115658_bib12","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1053\/j.gastro.2013.02.018","article-title":"Genomic decoding of intrahepatic cholangiocarcinoma reveals therapeutic opportunities","volume":"144","author":"Andersen","year":"2013","journal-title":"Gastroenterology"},{"issue":"2","key":"10.1016\/j.biopha.2023.115658_bib13","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1038\/s41575-018-0075-9","article-title":"Wnt-beta-catenin signalling in liver development, health and disease","volume":"16","author":"Perugorria","year":"2019","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"issue":"3","key":"10.1016\/j.biopha.2023.115658_bib14","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1172\/JCI76452","article-title":"WNT signaling drives cholangiocarcinoma growth and can be pharmacologically inhibited","volume":"125","author":"Boulter","year":"2015","journal-title":"J. Clin. Invest"},{"issue":"10","key":"10.1016\/j.biopha.2023.115658_bib15","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1111\/cas.12223","article-title":"Inhibition of Wnt\/beta-catenin signaling downregulates P-glycoprotein and reverses multi-drug resistance of cholangiocarcinoma","volume":"104","author":"Shen","year":"2013","journal-title":"Cancer Sci."},{"issue":"4","key":"10.1016\/j.biopha.2023.115658_bib16","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.3748\/wjg.v21.i4.1148","article-title":"beta-escin reverses multidrug resistance through inhibition of the GSK3beta\/beta-catenin pathway in cholangiocarcinoma","volume":"21","author":"Huang","year":"2015","journal-title":"World J. Gastroenterol."},{"issue":"8","key":"10.1016\/j.biopha.2023.115658_bib17","doi-asserted-by":"crossref","DOI":"10.3390\/cells12081141","article-title":"Impact of aberrant beta-catenin pathway on cholangiocarcinoma heterogeneity","volume":"12","author":"Lozano","year":"2023","journal-title":"Cells"},{"issue":"3","key":"10.1016\/j.biopha.2023.115658_bib18","first-page":"28","article-title":"The significance of genetics for cholangiocarcinoma development","volume":"1","author":"Maroni","year":"2013","journal-title":"Ann. Transl. Med"},{"issue":"2","key":"10.1016\/j.biopha.2023.115658_bib19","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.jhep.2020.03.008","article-title":"Molecular classification and therapeutic targets in extrahepatic cholangiocarcinoma","volume":"73","author":"Montal","year":"2020","journal-title":"J. Hepatol."},{"issue":"D1","key":"10.1016\/j.biopha.2023.115658_bib20","doi-asserted-by":"crossref","first-page":"D941","DOI":"10.1093\/nar\/gky1015","article-title":"COSMIC: the catalogue of somatic mutations in cancer","volume":"47","author":"Tate","year":"2019","journal-title":"Nucleic Acids Res"},{"issue":"6","key":"10.1016\/j.biopha.2023.115658_bib21","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1002\/humu.20495","article-title":"Impact of mutant p53 functional properties on TP53 mutation patterns and tumor phenotype: lessons from recent developments in the IARC TP53 database","volume":"28","author":"Petitjean","year":"2007","journal-title":"Hum. Mutat."},{"issue":"5","key":"10.1016\/j.biopha.2023.115658_bib22","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1158\/2159-8290.CD-12-0095","article-title":"The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data","volume":"2","author":"Cerami","year":"2012","journal-title":"Cancer Discov."},{"issue":"6","key":"10.1016\/j.biopha.2023.115658_bib23","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1021\/mp300028a","article-title":"No correlation between the expression of FXR and genes involved in multidrug resistance phenotype of primary liver tumors","volume":"9","author":"Martinez-Becerra","year":"2012","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.biopha.2023.115658_bib24","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1186\/1471-2164-15-74","article-title":"Comprehensive analysis of beta-catenin target genes in colorectal carcinoma cell lines with deregulated Wnt\/beta-catenin signaling","volume":"15","author":"Herbst","year":"2014","journal-title":"BMC Genom."},{"issue":"7264","key":"10.1016\/j.biopha.2023.115658_bib25","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1038\/nature08356","article-title":"Tankyrase inhibition stabilizes axin and antagonizes Wnt signalling","volume":"461","author":"Huang","year":"2009","journal-title":"Nature"},{"issue":"17","key":"10.1016\/j.biopha.2023.115658_bib26","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.1038\/onc.2013.169","article-title":"Small-molecule inhibition of CBP\/catenin interactions eliminates drug-resistant clones in acute lymphoblastic leukemia","volume":"33","author":"Gang","year":"2014","journal-title":"Oncogene"},{"issue":"1","key":"10.1016\/j.biopha.2023.115658_bib27","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1186\/1756-9966-32-100","article-title":"XAV939, a tankyrase 1 inhibitior, promotes cell apoptosis in neuroblastoma cell lines by inhibiting Wnt\/beta-catenin signaling pathway","volume":"32","author":"Tian","year":"2013","journal-title":"J. Exp. Clin. Cancer Res"},{"issue":"5","key":"10.1016\/j.biopha.2023.115658_bib28","doi-asserted-by":"crossref","DOI":"10.3390\/ph14050421","article-title":"Royer, ICG-001, an Inhibitor of the beta-Catenin and cAMP response element-binding protein dependent gene transcription, decreases proliferation but enhances migration of osteosarcoma cells","volume":"14","author":"Danieau","year":"2021","journal-title":"Pharmaceuticals"},{"issue":"39","key":"10.1016\/j.biopha.2023.115658_bib29","doi-asserted-by":"crossref","first-page":"4192","DOI":"10.2174\/1381612825666191112142943","article-title":"Wnt-beta-catenin signaling pathway, the achilles' heels of cancer multidrug resistance","volume":"25","author":"Ghandadi","year":"2019","journal-title":"Curr. Pharm. Des."},{"issue":"3","key":"10.1016\/j.biopha.2023.115658_bib30","doi-asserted-by":"crossref","first-page":"2543","DOI":"10.3892\/mmr.2016.4882","article-title":"beta-Catenin signaling pathway regulates cisplatin resistance in lung adenocarcinoma cells by upregulating Bcl-xl","volume":"13","author":"Zhang","year":"2016","journal-title":"Mol. Med Rep."},{"key":"10.1016\/j.biopha.2023.115658_bib31","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/j.lfs.2018.07.023","article-title":"BCL9 promotes epithelial mesenchymal transition and invasion in cisplatin resistant NSCLC cells via beta-catenin pathway","volume":"208","author":"Zhang","year":"2018","journal-title":"Life Sci."},{"issue":"3","key":"10.1016\/j.biopha.2023.115658_bib32","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1002\/hep.31829","article-title":"Genetic determinants of outcome in intrahepatic cholangiocarcinoma","volume":"74","author":"Boerner","year":"2021","journal-title":"Hepatology"},{"issue":"4","key":"10.1016\/j.biopha.2023.115658_bib33","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1002\/hep.31110","article-title":"Genomic characterization of cholangiocarcinoma in primary sclerosing cholangitis reveals therapeutic opportunities","volume":"72","author":"Goeppert","year":"2020","journal-title":"Hepatology"},{"issue":"12","key":"10.1016\/j.biopha.2023.115658_bib34","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1080\/14728222.2021.2013801","article-title":"Molecular characterization of extrahepatic cholangiocarcinoma: perihilar and distal tumors display divergent genomic and transcriptomic profiles","volume":"25","author":"Simbolo","year":"2021","journal-title":"Expert Opin. Ther. Targets"},{"issue":"5","key":"10.1016\/j.biopha.2023.115658_bib35","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1016\/j.jhep.2018.01.009","article-title":"Genomic characterization of biliary tract cancers identifies driver genes and predisposing mutations","volume":"68","author":"Wardell","year":"2018","journal-title":"J. Hepatol."},{"issue":"21","key":"10.1016\/j.biopha.2023.115658_bib36","doi-asserted-by":"crossref","DOI":"10.3390\/ijms222111774","article-title":"The Role of TP53 in cisplatin resistance in mediastinal and testicular germ cell tumors","volume":"22","author":"Timmerman","year":"2021","journal-title":"Int J. Mol. Sci."},{"issue":"3","key":"10.1016\/j.biopha.2023.115658_bib37","first-page":"556","article-title":"Association between cisplatin resistance and mutation of p53 gene and reduced bax expression in ovarian carcinoma cell systems","volume":"56","author":"Perego","year":"1996","journal-title":"Cancer Res"},{"issue":"9","key":"10.1016\/j.biopha.2023.115658_bib38","doi-asserted-by":"crossref","first-page":"5462","DOI":"10.1245\/s10434-022-11932-3","article-title":"Drug-eluting bead, irinotecan therapy of unresectable intrahepatic cholangiocarcinoma (DELTIC) with concomitant systemic gemcitabine and cisplatin","volume":"29","author":"Martin","year":"2022","journal-title":"Ann. Surg. Oncol."},{"issue":"11","key":"10.1016\/j.biopha.2023.115658_bib39","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.4161\/cbt.5.11.3271","article-title":"Transcriptional activation of the carboxylesterase 2 gene by the p53 pathway","volume":"5","author":"Choi","year":"2006","journal-title":"Cancer Biol. Ther."},{"key":"10.1016\/j.biopha.2023.115658_bib40","doi-asserted-by":"crossref","first-page":"5280736","DOI":"10.1155\/2018\/5280736","article-title":"The relationship between TP53 gene status and carboxylesterase 2 expression in human colorectal cancer","volume":"2018","author":"Ishimine","year":"2018","journal-title":"Dis. Markers"},{"issue":"6453","key":"10.1016\/j.biopha.2023.115658_bib41","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1126\/science.aax3649","article-title":"A dominant-negative effect drives selection of TP53 missense mutations in myeloid malignancies","volume":"365","author":"Boettcher","year":"2019","journal-title":"Science"},{"issue":"6","key":"10.1016\/j.biopha.2023.115658_bib42","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1007\/s10585-007-9084-8","article-title":"p53 dominant-negative mutant R273H promotes invasion and migration of human endometrial cancer HHUA cells","volume":"24","author":"Dong","year":"2007","journal-title":"Clin. Exp. Metastas-.-."},{"issue":"5","key":"10.1016\/j.biopha.2023.115658_bib43","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2022.100573","article-title":"Phase Ib study of eprenetapopt (APR-246) in combination with pembrolizumab in patients with advanced or metastatic solid tumors","volume":"7","author":"Park","year":"2022","journal-title":"ESMO Open"}],"container-title":["Biomedicine & Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332223014567?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332223014567?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T21:40:37Z","timestamp":1779918037000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0753332223014567"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12]]},"references-count":43,"alternative-id":["S0753332223014567"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2023.115658","relation":{},"ISSN":["0753-3322"],"issn-type":[{"value":"0753-3322","type":"print"}],"subject":[],"published":{"date-parts":[[2023,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Evaluation of potential targets to enhance the sensitivity of cholangiocarcinoma cells to anticancer drugs","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2023.115658","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"115658"}}